How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML)-Reference-Cited by-同舟云学术

How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML)

Published:2020-10-15 Issue:2 Volume:193 Page:231-244
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br. J. Haematol.

Author:

Dillon Richard¹²,Potter Nicola¹,Freeman Sylvie³,Russell Nigel²^ORCID

Affiliation:

1. Cancer Genetics Laboratory Department of Medical and Molecular Genetics King’s College LondonUK

2. Department of Haematology Guy’s and St Thomas’ Hospitals NHS Trust LondonUK

3. Institute of Immunology and Immunotherapy University of Birmingham Birmingham UK

Funder

Cancer Research UK

National Institute for Health Research

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17185

Reference100 articles.

1. Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations

2. Assessment of Minimal Residual Disease in Standard-Risk AML

3. Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia

4. A single versus fractionated schedule of gemtuzumab ozogamicin in combination with daunorubicin / Ara‐C as induction therapy in older patients with AML: results from the UK NCRI AML18 Trial;Russell N;Eur Soc Haematol,2020

5. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Role and Clinical Utility of Measurable Residual Disease in Acute Myeloid Leukemia;Advances in Oncology;2024-05

2. SOHO State of the Art Updates and Next Questions: Pre-emptive Therapy at Molecular Measurable Residual Disease Failure in Acute Myeloid Leukemia;Clinical Lymphoma Myeloma and Leukemia;2024-03

3. Acute Myeloid Leukemia and Next-Generation Sequencing Panels for Diagnosis: A Comprehensive Review;Journal of Pediatric Hematology/Oncology;2024-02-29

4. Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC‐MRD and treatment guidance for elderly patients;European Journal of Haematology;2024-02-11

5. Minimal Residual Disease in Acute Myeloid Leukemia: Old and New Concepts;International Journal of Molecular Sciences;2024-02-10